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Previous studies infecting global IL-4Rα−/−, IL-4−/−, and IL-13−/−mice on a
BALB/c background with the visceralizing parasite Leishmania donovani have
shown that the T helper 2 cytokines, IL-4, and IL-13, play influential but not
completely overlapping roles in controlling primary infection. Subsequently, using
macrophage/neutrophil-specific IL-4Rα deficient BALB/c mice, we demonstrated that
macrophage/neutrophil unresponsiveness to IL-4 and IL-13 did not have a detrimental
effect during L. donovani infection. Here we expand on these findings and show that
CD4+ T cell-(Lckcre), as well as pan T cell-(iLckcre) specific IL-4Rα deficient mice, on a
BALB/c background, unlike global IL-4Rα deficient mice, are also not adversely affected
in terms of resistance to primary infection with L. donovani. Our analysis suggested only
a transient and tissue specific impact on disease course due to lack of IL-4Rα on T cells,
limited to a reduced hepatic parasite burden at day 30 post-infection. Consequently,
the protective role(s) demonstrated for IL-4 and IL-13 during L. donovani infection are
mediated by IL-4Rα-responsive cell(s) other than macrophages, neutrophils and T cells.
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INTRODUCTION
Infection with the parasite Leishmania donovani causes visceral disease and can be fatal if it is
not treated. Although there are major campaigns aimed at eliminating this disease e.g., World
Health Organization 2020 roadmap, it still remains a serious neglected tropical disease (1) (https://
www.who.int/leishmaniasis/en/), with no effective vaccine currently available (2). Successful
pathogenesis is dependent on parasite survival in the host, a process mediated by a complex
interplay of host factors. An in-depth understanding on the contribution of these factors to disease
is therefore necessary to inform the development of novel or adjunct host-directed therapies (3, 4).
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Earlier studies in this context revealed that the IFN-γ/IL-
4 paradigm of resistance and susceptibility to intracellular
infection, as defined for species causing cutaneous leishmaniasis
(CL), does not apply holistically to species causing visceral
leishmaniasis (VL). As with CL, protective immunity against
this parasite relies on a Th1 response, which requires IL-
12 production, and culminates in IFN-γ release (5, 6). In
target tissues such as the liver, infection results in granuloma
formation around infected macrophages (Kupffer cells) and
eventual parasite death, primarily via the action of reactive
nitrogen and oxygen intermediates (7, 8). However, unlike CL,
a dominant inhibitory role for type 2 cytokines is less clear
in murine models of VL (9). In asymptomatic and cured VL
patients (10–12), both IFN-γ and IL-4-producing T cells have
been identified and in the murine model of VL, protection is
related to higher frequencies of cytokine-producing cells rather
than altering the IFN-γ/IL-4 balance (13). In contrast, both
human (12, 13) and murine (14) VL studies show that IL-
10 is more important than IL-4 in immune suppression and
parasite persistence.
Rather than being a detrimental cytokine for host protection,
the evidence tends to suggest that type 2 immune responses
may actually contribute to control of VL. Accordingly, our
previous studies utilizing gene-deficient mice have identified
protective roles for IL-4, IL-13, and IL-4Rα signaling during
primary L. donovani infection (15–17). Control of parasite
growth within the liver depends on the ability of Kupffer cells
to clear parasites inside mature granulomas (15), a mechanism
which requires T cell-derived IFN-γ (18) and the coordinated
activity of macrophages which migrate toward the infected area.
Enhanced susceptibility of IL-4−/−, IL-13−/−, and IL-4Rα−/−
mice to L. donovani infection was associated with a reduction
in type 1 responses and retarded granuloma maturation so
that fewer mature or sterile granulomas were present (15, 16,
19). In line with these observations, a recent study indicated
that IL-10, and not IL-4, was responsible for manipulating
monocytes/macrophages in VL infection (20). In addition to
playing significant roles in controlling primary infection with
L. donovani, IL-4, and IL-13 have also been associated with the
successful outcome of sodium stibogluconate (SSG) treatment
and vaccination with recombinant hydrophilic acylated surface
protein (HASP)B-1 (15, 17, 19). While these studies added value
to our understanding of the contribution of IL-4/IL-13 in host-
protection against VL, they did not provide information on
which cells were targeted by these cytokines via the IL-4Rα, and
are therefore critical for protective immunity. Indeed, both IL-
4 and IL-13 are pleiotropic cytokines and numerous cell types
of both the innate and adaptive immune system produce and
respond to these cytokines (21). In this regard, studies in cell-
type specific IL-4Rα-deficient mice during CL has revealed a
hierarchical interaction between the IL-4Rα chain and its ligands
on different immune cells. To illustrate this, IL-4Rα signaling via
DCs to produce IL-12 plays a protective role during cutaneous
infection with Leishmania major (22), while IL-4Rα signaling via
T cells (23) and Th2 induction, via macrophages and alternative
activation (24), and via B cells and IL-4 production (25), all
promote disease progression.
To further dissect the cell-specific requirements of IL-
4/IL-13 signals on immune cells in VL, we used conditional
cell-specific IL-4Rα deficient BALB/c mice, generated by
the cre/loxP recombination system, to demonstrate that
macrophage/neutrophil-specific (LysM) IL-4Rα signaling was
not necessary for an effective healing response during VL, nor
did it influence the outcome of SSG chemotherapy (16). Other
possible target cells for IL-4 during VL may include dendritic
cells (DC) (26, 27) and B cells (28) but more particularly CD4+
(26, 29) and/or CD8+ (30) T cells, whose active involvement
has been shown not only to be essential to control primary
infection and granuloma formation but also for successful
SSG chemotherapy and therapeutic vaccination (15, 31, 32).
Consequently, in this study we generated CD4+ T cell-specific
IL-4Rα−/− (LckcreIL-4Rα−/lox) mice (23) and iLckcreIL-
4Rα−/lox mice that lack IL-4Rα on both CD4 and CD8T cells
(33) to determine the temporal role of IL-4 signaling via CD4+
and CD8+ T cells on the progression of VL infection. Unlike
global IL-4Rα−/− mice infected with L. donovani that developed
significantly higher parasite burdens than wild-type mice in
this and previous studies (15), CD4+ T cell specific IL-4Rα−/−
mice were by comparison resistant to infection. Indeed, at day
30 post-infection CD4+ T cell as well as pan T cell-specific
IL-4Rα−/lox mice (iLckcreIL-4Rα−/lox) were more. resistant than
their wild-type littermate controls to hepatic infection with L.
donovani. Increased susceptibility in global IL-4Rα−/− mice
was associated with a diminished type 1 response and increased
IL-10 production while CD4+ T cell deficient IL-4Rα−/lox mice
had comparable expression of IFN-γ on both CD4+ and CD8+
T cells and serum IL-10 levels similar to infected wild-type mice.
Consequently, the protective effects of IL-4 during primary
L. donovani infection are not mediated via direct effects on
either CD4+ or CD8+ T cells, and IL-4 may even play a small
regulatory role in these cells.
MATERIALS AND METHODS
Ethics Statement
Animal experiments and experimental procedures were carried
out in line with UK Home Office regulations and the University
of Strathclyde Animal Welfare and Ethical Review Board
regulations under project license number: PPL 60/3525. BALB/c
mice were all bred and maintained in the Biological Procedures
Unit at the University of Strathclyde, Glasgow and experimental
design and reporting adhere to the ARRIVE guidelines.
Animals and Parasites
LckcreIL-4Rα−/lox BALB/c mice were created as described (23).
Briefly, LckcreIL-4Rα−/lox mice were generated by inter-crossing
IL-4Rαlox/lox BALB/c mice (34) with IL-4Rα−/− BALB/c mice
(35) and BALB/c mice expressing the Cre-recombinase under
the control of Lck locus, a T cell specific promoter (36) to
generate hemizygous LckcreIL-4Rα−/lox mice. The efficiency of
the deletion was characterized (23) whereby LckcreIL-4Rα−/lox
BALB/c mice have IL-4Rα selectively deleted from CD4+ T cells
(CD4+ T cell specific IL-4Rα deficient mice). As these mice have
variable and incomplete deletion in CD8+ T cells (28), mice
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lacking the IL-4Rα on all T cells (iLckcreIL-4Rα−/lox mice) were
produced as described (33). The iLckcre construct was designed
with a nuclear localization signal and an eukaryotic translation
start site at the 5’ end of the Cre-recombinase, which meant
that the insert integrated downstream from the Lck proximal
promoter (33, 37). Non-T cell populations such as B cells,
macrophages and DC express IL-4Rα as normal. PCR genotyping
studies were used to identify LckcreIL-4Rα−/lox mice. Lckcre-
negative IL-4Rα−/lox littermate BALB/c mice, which express
similar levels of IL-4Rα as wild-type BALB/c mice, were used
as controls to iLckcreIL-4Rα−/lox mice, herein referred to as
wild-type (WT) littermate control.
Commercially obtained Golden Syrian hamsters (Mesocricetus
auratus) were used for maintenance of L. donovani (Harlan Olac,
Bicester, UK) and L. donovani strain MHOM/ET/67:LV82 was
used in these studies (38). Mice, age and sex-matched, were coded
and randomized before injection to avoid bias. The mice were
infected (day 0) by intravenous injection into the tail vein without
using an anesthetic with 1–2× 107 L. donovani amastigotes (16).
Depending on the experiment, mice were killed (n = 4/5 per
group) at days 14 or 15, 30, and 56 or 60 post-infection (p.i.).
In vivo Studies
Liver, spleen, and bone marrow impression smears from each
mouse were prepared on a glass microscope slide at sacrifice.
The slides were fixed in methanol for 2min, stained with a 10%
Giemsa solution (BDH, VWR International Ltd, UK) for 20min,
washed in tap water and allowed to dry. The number of parasites
/1,000 host nuclei for each sample was determined at ×1,000
magnification. Blood was collected from each mouse at sacrifice
and left to clot. The resulting serum was harvested, stored at
−20◦C, and then used in assays to determine specific antibody
titers and cytokine levels.
Spleen Cell Proliferation Assays
Mouse spleens were removed aseptically at sacrifice, and
processed as described previously (16). Splenocytes, seeded at 5
× 105 cells/well, were incubated at 37◦C and 5% CO2/95% air
for 72 h with medium alone (unstimulated controls), 25µg/ml
L. donovani promastigote soluble antigen (SAG) or 10µg/ml
ConA (Sigma-Aldrich, Poole, UK). The plates were then stored at
−20◦C and cell supernatants were used in cytokine/nitrite assays.
Cytokine Production
Enzyme-linked immunosorbent assays (ELISA) was used to
determine IFN-γ levels in splenocytes supernatants from
lymphocyte proliferation assays and serum samples using the
method described (19). A volume of 50 µl/well of 1µg/ml w/v
of the appropriate purified anti-mouse capture antibody [IL-10
JES5-2AS and IFNγ R4-6A2 (PharMingen, supplied by Insight
Biotechnology, Wembley, UK) or IL-13 38213 (R&D Systems
Europe Ltd, Abingdon, UK)] and 100 µl/well of the appropriate
biotinylated rat anti-mouse monoclonal antibody at 2µg/ml [IL-
10 SXC-1 and IFNγ XMG1-2 (PharMingen, supplied by Insight
Biotechnology, Wembley, UK) or IL-13 (R&D Systems Europe
Ltd, Abingdon, UK)] was used in assays. The absorbance of the
samples was read at 405 nm using a SOFTmax Pro (Molecular
devices, California, USA) and cytokine concentrations (ng/ml) in
samples was determined by linear regression using the standard
values. In all cases the correlation coefficient was 0.970 or better.
Specific Antibody Titers
Specific IgG1 and IgG2a titers were determined for serum
samples using the method described previously (16). Plates
were coated with 100 µl/well of 10µg/ml L. donovani SAG
and probed using anti-mouse IgG1 (1:20,00 dilution) or IgG2a
(1:10,000 dilution) HRP conjugates (Southern Biotechnology,
supplied by Cambridge BioScience Ltd, Cambridge, UK). The
absorbance of samples was determined at 450 nm using a
SOFTmax Pro (Molecular devices, California, USA) and end
point titers, defined as the last dilution to give an absorbance
above background levels, was determined.
Determination of IgE Production
A 96 well microtiter plate (Greiner Bio-One, Germany) was
coated with 50 µl/well of 1µg/ml IgE purified anti-mouse
capture antibody (clone R35-72 obtained from PharMingen and
supplied by Insight Biotechnology, Wembley, UK) diluted in
PBS pH 9.0 and incubated at 4 ◦C overnight. The plate was
washed three times with PBS supplemented with 0.05% v/v
Tween 20 (Sigma-Aldrich, Poole, UK), dried and blocked with
10% v/v FCS/PBS. Following addition of 200µl/well the plate was
incubated at 37◦C for 1 h. The plate was washed 3 times, dried
and serum samples diluted at 1/50 were serially diluted in 10%
v/v FCS/PBS along the plate. The plate was incubated at 37◦C for
2 h. Following incubation, the plate was washed 4 times and 100
µl/well of a biotinylated rat anti-mouse IgEmonoclonal antibody
(clone R35-118 obtained from PharMingen and supplied by
Insight Biotechnology, Wembley, UK) diluted 1/5,000 in 10% v/v
FCS/PBS was added to the plate. The plate was then incubated
at 37◦C for 1 h. The plate was washed 5 times and 100 µl/well
of streptavidin alkaline phosphatase (obtained from PharMingen
and supplied by Insight Biotechnology, Wembley, UK) diluted at
1/2,000 in 10% v/v FCS/PBS was added. The plate was incubated
at 37◦C for 45min. The plate was washed 6 times and 100 µl/well
of substrate (1 mg/ml p-nitrophenylphosphate (Sigma-Aldrich,
Poole, UK) in 0.1M glycine buffer, pH 10.4) was added. The plate
was incubated in the dark at 37◦C until an appropriate yellow
color developed. The absorbance of the samples at 405 nm was
determined using a SOFTmax Pro (Molecular devices, California,
USA) and the endpoint dilution determined as described above.
Histology
Sections of liver were removed at sacrifice, fixed in neutral
buffered formalin, and then processed for staining with
Haematoxylin and Eosin (Fisher Scientific, Loughborough, UK).
Granulomas were scored on their level of maturity based
on the following criteria; infected Kupffer cells (parasitized
macrophages), immature (developing granuloma consisting of
CD4+ and CD8+ T cells and monocytes surrounding infected
Kupffer cells), mature (more developed than immature) or sterile
(parasite free granuloma) (39).
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Flow Cytometry
The percentage of CD4+IFNγ+ and CD8+IFNγ+ cells present in
the spleen of mice was determined by flow cytometry. Single cell
suspensions were prepared from the spleens of uninfected and
infectedmice in complete medium [RPMI 1640 (Lonza, Belgium)
supplemented with 1% v/v of 2mM L-glutamine solution and
1% v/v of 100 IU/ml Penicillin-100µg/ml Streptomycin (PAA
Laboratories, GmbH, Austria), and 10% v/v FCS (Sigma Aldrich,
Poole, UK)]. Cell suspensions were pelleted by centrifugation at
1,000 rpm, 4◦C for 5min and the pellets were resuspended in
3ml of erythrocyte lysing solution (0.007M ammonium chloride,
0.085M Tris, pH 7.2). Cell suspensions were incubated at 37◦C
for 5min, washed three times in complete medium, and then
resuspended at a concentration of 1 × 106/ml. The cells were
incubated for 4 h with 2 µl/ml Brefeldin A (BD Biosciences,
UK), 500 ng/ml ionomycin and 50 ng/ml phorbol 12-mysristate
13 acetate (Sigma Aldrich, Poole, UK) at 37◦C and 5% CO2. The
cells were then washed with FACS buffer (5% w/v Bovine serum
albumin, Fraction V (Sigma Aldrich, Poole, UK), 2mM EDTA in
PBS pH 7.4) for 5min at 500 g, and then resuspended in FACS
buffer containing 1µg/ml purified rat anti-mouse CD16/CD32
(FCγ111/11 receptor) monoclonal antibody (BD Biosciences,
Oxford, UK) and incubated for 20min. The cells were washed
as before and stained with the appropriate anti-mouse antibody
diluted in FACS buffer (0.5µg/ml PerCP-labeled anti-CD4+
or 1µg/ml APC-labeled anti-CD8+ or 0.5µg/ml PerCP and
1µg/ml APC-labeled IgG isotype controls, BD Biosciences,
Oxford, UK) in the dark for 60min at 4◦C. Cells were washed
three times and then incubated with a 10% v/v cell lysing solution
diluted in distilled water (BD Biosciences, Oxford, UK) for
10min in the dark. The cells were washed again and incubated
for a further 10min in the dark with a 10% v/v permeabilizing
solution diluted in distilled water (BD Biosciences, Oxford UK).
Following this incubation, cells were washed and resuspended
in 2µg/ml purified rat anti-mouse CD16/CD32 (FCγ111/11
receptor) monoclonal antibody (BD Biosciences, Oxford, UK)
diluted in FACS buffer. After a 10min incubation, PE-labeled
anti-mouse IFNγ (final concentration 2µg/ml) and PE-labeled
IgG isotype control (final concentration 2µg/ml, BD Biosciences,
Oxford, UK) diluted in 10% v/v permeabilizing solution was
added to the appropriate sample and the cells were incubated for
60min. The cells were washed once more, and then resuspended
in 400 µl of a 10% v/v cell fix solution diluted in distilled water
(BD Biosciences, Oxford, UK). The number of positive staining
cells for a specific marker was determined using a FACSCantoTM
(BD Biosciences, Oxford, UK). Color compensation using BDTM
Compbeads and the antibodies used to stain cells was carried out
before cell data was collected based on forward and side scatter
using FACsDivaTM software.
Statistical Analysis of Data
Downstream data analysis was performed blind to treatment
group and experiments were repeated at least twice when
significant differences between treatments were obtained.
Parasite burden from in vivo experiments were analyzed using
a one-way ANOVA using log10 transformed data, followed by
a Fisher’s PLSD test to analyze differences between treatments
using Statview R© version 5.0.1 software package. Significant
FIGURE 1 | Parasite burdens in wild-type (IL-4Rα−/lox), CD4T cell-specific IL-4Rα deficient (Lckcre IL-4Rα−/lox), and IL-4Rα−/− BALB/c mice were determined at
days 30 and 56 post-infection with 1–2 × 107 L. donovani amastigotes in the liver (A), spleen (B), and bone marrow (C) by LDU. Representative data from one of
three experiments performed (n = 5/group). *p < 0.05, **p < 0.01, ***p < 0.001 compared to WT control (IL-4Rα−/lox), #p < 0.05 Lckcre IL-4Rα−/lox compared
to IL-4Rα−/−.
Frontiers in Immunology | www.frontiersin.org 4 August 2019 | Volume 10 | Article 1957
McFarlane et al. IL-4Rα+ T Cells in Visceral Leishmaniasis
differences between treatments for cytokine and flow cytometry
data were identified using a Kruskal Wallis test followed by a
Tukey test. Granuloma maturation data was analyzed using a χ2
test and the mean % granulomas in the Kupffer cell, immature,
mature and sterile categories. Data was analyzed using Minitab
ExpressTM version 1.51 software package and a p < 0.05 was
considered significant.
RESULTS
A Protective Role for IL-4 During L.
donovani Infection Involves Cell Targets
Other Than CD4+ T Cells
CD4+ T cell-specific IL-4Rα deficient (LckcreIL-4Rα−/lox) and
wild-type littermate control (IL-4Rα−/lox) and global IL-4Rα−/−
BALB/c mice were infected with L. donovani on day 0 and
parasite burdens in the spleen, liver, and bone marrow were
FIGURE 2 | CD4+ T cell specific IL-4Rα−/lox (Lckcre IL-4Rα−/lox), wild-type
control (IL-4Rα−/lox), and global IL-4Rα−/− BALB/c mice were infected with
L. donovani on day 0 post-infection and sacrificed at days 30 (A) and 56 (B)
post-infection. At each time-point, sections of liver were removed, processed,
and stained with haematoxylin and eosin to enable scoring of hepatic liver
granulomas. Representative data from one of two experiments performed (n =
5/group). On day 30 (A) the distribution was significantly different for control
and global IL-4Rα−/− mice (χ2 = 44; p < 0.00001) and CD4+ T cell specific
IL-4Rα−/lox (Lckcre IL-4Rα−/lox) and global IL-4Rα−/− mice (χ2 = 63; p <
0.00001). On day 56 (B) the distribution was significantly different for control
and global IL-4Rα−/− mice (χ2 = 46; p < 0.00001) and CD4+ T cell specific
IL-4Rα−/lox (Lckcre IL-4Rα−/lox) and global IL-4Rα−/− mice (χ2 = 30;
p < 0.00001).
determined, on day 14/15, 30, and 56/60 p.i. All three mouse
strains had similar parasite burdens in the spleen, liver, and bone
marrow at early times p.i. (day 14 or 15;Table S1), indicating that
the inability to signal through IL-4Rα on CD4+ T cells did not
interfere with establishment and early control of infection in the
spleen, liver, and bone marrow.
At day 30 p.i., CD4+ T cell IL-4Rα deficient mice and
littermate controls had comparable parasite burdens in the spleen
and bone marrow. However, CD4+ T cell IL-4Rα deficient mice
had significantly lower liver parasite burdens than WT littermate
control and global IL-4Rα−/− BALB/c mice (Figure 1) at this
time. This effect was transient however, and by day 56 parasite
burdens in all three sites was comparable between WT and
CD4+ T cell-specific IL-4Rα deficient mice. In contrast, and as
expected (15), global IL-4Rα−/−mice weremore susceptible to L.
donovani infection and this was exhibited by significantly higher
parasite burden at later time points in all target tissues (Figure 1).
Thus, selective deficiency of IL-4Rα expression in CD4+ T cells
had a temporary protective effect, which was only expressed in
the liver, but did not alter the overall susceptibility to VL.
IL-4 Signaling Via CD4+ T Cells Is Not a
Requirement for Effective Hepatic
Granuloma Formation Following L.
donovani Infection
Granuloma formation in livers of L. donovani infected mice
was assessed at days 15, 30, and 56 post-infection in CD4+
T cell specific IL-4Rα deficient (LckcreIL-4Rα−/lox), wild-type
littermate control (IL-4Rα−/lox) and global IL-4Rα−/− BALB/c
mice. At day 15 post-infection, although granuloma development
was evident, the granulomas were at an immature stage and, as
such, no significant differences between groups were observed
(Table S2). At day 30 post-infection, however, CD4+ T cell-
specific IL-4Rα deficient mice and wild-type controls showed
evidence of granuloma maturation, as defined by an increased
number of mature and sterile granulomas, compared with
global IL-4Rα−/− mice (Figure 2A). Similarly, at day 56, the
frequency of mature and sterile granulomas had increased and
was similar in CD4+ T cell-specific IL-4Rα deficient mice and
wild-type control mice, reflecting a similar ability to control
liver parasite burdens by this time point (Figure 2B). Granuloma
maturation was significantly retarded in global IL-4Rα−/− but
not CD4 T cell-specific compared with WT mice at both time
points (p < 0.00001). Representative photomicrographs show
granuloma formation in each group at days 15 (Figure S1), 30
(Figures 3A–C) and day 56 (Figures 3D–F) post-infection.
Th2/type 2 Immune Responses Are
Unchanged in CD4T Cell-Specific IL-4Ra
Deficient Mice in Response to L.
donovani-induced VL
An inability of global IL-4Rα−/−mice to control parasite burdens
or develop a mature and effective granulomatous response has
previously been associated with a down-regulation in serum
IFN-γ production (15). In the present study we therefore
measured production of IFN-γ by antigen-stimulated spleen
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FIGURE 3 | Representative photomicrographs of the hepatic granuloma response at days 30 and 56 in L. donovani infected wild-type (IL-4Rα−/lox) (A,D), CD4+ T
cell specific IL-4Rα−/lox (Lckcre IL-4Rα−/lox) (B,E) and global IL-4Rα−/− mice (C,F). Mature granulomas (arrows) in IL-4Rα−/lox mice and Lckcre IL-4Rα−/lox mice are
shown in day 30 whilst global IL-4Rα−/− mice show abrogated granuloma development characterized by immature granulomas and amastigotes within the
cytoplasm of infected Kupffer cells (arrows). At day 56 post-infection, IL-4Rα−/lox mice and Lckcre IL-4Rα−/lox mice show sterile granulomas (arrows) whilst heavily
parasitized immature granulomas remain in the livers of global IL-4Rα−/− mice (arrows). Magnification 400×.
cells and the frequency of CD4+IFN-γ+ and CD8+IFN-γ+
splenocytes of each mouse group after stimulation with PMA
and ionomycin, as a measure of commitment to cytokine
production during infection. On day 30 post-infection, we
found no significant difference in the amount of IFN-γ [ng/ml]
produced by antigen-stimulated splenocytes from any group of
mice, WT controls (0.207 ± 0.030), CD4+ T cell specific IL-
4Rα deficient mice (0.331 ± 0.049), global IL-4Rα−/− mice
(0.482 ± 0.076). However, using flow cytometry to examine
intracellular cytokine production at this time revealed that
the percentages of CD4+IFN-γ+ splenocytes (Figure 4A) and
CD8+/IFN-γ+ splenocytes (Figure 4B) in global IL-4Rα−/−
mice were significantly lower (CD4+IFN-γ+, p < 0.05;
CD8+IFN-γ+, p < 0.02) than observed in WT controls while
the frequency of CD8+/IFN-γ+ splenocytes in global IL-4Rα−/−
mice was also reduced compared with CD4+ T cell specific IL-
4Rα−/− mice (p < 0.01, Figure 4B). This pattern was repeated
on day 60 post-infection, (e.g., p < 0.0001 for global IL-4Rα−/−
mice vs. CD4+ T cell-specific IL-4Rα-deficient mice). There
was no significant difference measured in the frequency of
CD4+IFN-γ+ and CD8+IFN-γ+ cells between CD4+ T cell
specific IL-4Rα deficient mice and wild-type controls at all time
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FIGURE 4 | CD4+ T cell specific IL-4Rα deficient (Lckcre IL-4Rα−/lox),
wild-type control (IL-4Rα−/lox) and global IL-4Rα−/− mice were sacrificed at
days 30 and 60 post-infection. At each time-point, splenocytes were removed,
stimulated with ionomycin and PMA in the presence of brefeldin A, and the
percentage of IFN-γ secreting CD4+ (A) and CD8+ (B) cells were measured
by flow cytometry. Representative data from one of two experiments
performed. **p < 0.01, ***p < 0.001 compared to WT control (IL-4Rα−/lox),
##p < 0.01, ###p < 0.001 Lckcre IL-4Rα−/lox compared to IL-4Rα−/−.
points. Together, these data indicate that IFN-γ-responses in
LckcreIL-4Rα−/lox mice developed fully in the absence of IL-
4Rα+ signaling on CD4+ T cells when compared with wild-
type mice over the course of infection. Moreover, enhanced
susceptibility to L. donovani infection in global IL-4Rα−/− mice
is associated with reduced IFN-γ secretion by CD4+ and CD8+
T cells.
IL-10 levels are associated with susceptibility to L. donovani
infection (14), thus, IL-10 levels were measured in cell
supernatants of antigen-stimulated spleen cells and in the
serum from CD4+ T cell specific IL-4Rα deficient mice, wild-
type control mice and global IL-4Rα−/− mice at days 15, 30,
and 56 post-infection. There was no significant difference in
the amount of IL-10 [ng/ml] produced by antigen-stimulated
cells from any group of mice at day 30, WT controls (0.281
± 0.075), CD4+ T cell specific IL-4Rα deficient mice (0.231
± 0.026), and global IL-4Rα−/− mice (0.230 ± 0.013). In
addition, while similar levels of IL-10 were present in the
serum of all three groups of mice at day 15 p.i, by day 30
p.i significantly lower concentrations of IL-10 were present
in the serum of wild-type control (p < 0.01) and CD4+ T
cell specific IL-4Rα deficient mice (p < 0.01) compared with
global IL-4Rα−/− mice (Figure 5). This pattern was repeated
on day 56 post-infection. This data suggests that the relative
resistance observed in CD4+ T cell specific IL-4Rα deficient
and littermate control mice, in comparison to highly susceptible
global IL-4Rα−/− mice, is associated with comparatively limited
IL-10 production.
CD4+ T Cell Specific IL-4Rα-deficient Mice
Develop L. donovani-specific IgG1 and IgE
Antibody Responses Similar to WT Control
Mice
L. donovani-specific IgG1 and IgG2a levels and total serum IgE
levels were measured in CD4+ T cell specific IL-4Rα−/− mice,
wild-type control and global IL-4Rα−/− mice at days 15, 30,
and 56 post-infection. There was no difference in specific IgG1
or IgG2a in the three groups of mice at day 14 post-infection
(Figures 6A,B). However at day 30 p.i., global IL-4Rα−/−
produced significantly lower levels (p < 0.0.01) of antigen-
specific IgG1 but significantly higher IgG2a levels compared
with CD4+ T cell specific IL-4Rα deficient mice and wild-type
controls. In contrast, IgG1 and IgG2a titers were similar in
CD4+ T cell specific IL-4Rα deficientmice andwild-type controls
(Figures 6A,B). On day 60 p.i., both global and CD4+ T cell
specific IL-4Rα−deficient mice had significantly lower IgG1 titers
compared with WT controls (p< 0.05). IgG2a titers were similar
in all three groups of mice (Figures 6A,B). Comparison of the
ratio of IgG2a:IgG1 showed that global IL-4Rα−/− mice had
a higher ratio at days 30 (p < 0.01) and 56 (p < 0.001) p.i.
compared with WT and CD4+ T cell specific IL-4Rα deficient
mice (Figure 6C). Both CD4+ T cell specific IL-4Rα deficient
mice and wild-type control mice produced comparable amounts
of IgE on days 30 and 56 post-infection (Figure 6D). In contrast,
no serum IgE was detected for global IL-4Rα−/− mice any day
post-infection (Figure 6D). Based on this antibody data, it can
be concluded that the inability to signal through the IL-4Rα on
CD4+ T cells did not prevent a specific type 2 antibody response
whereas the inability to class switch in the global IL-4Rα−/− mice
resulted in a reduced type 2-antibody response.
Pan T Cell-Specific IL-4Rα Deficient Mice
Remain Comparatively Resistant to VL
Compared With Mice Globally Deficient for
IL-4/IL-13 Signaling
As CD4+ T cell-specific IL-4Rα-deficient mice remain positive
for IL-4Rα expression on CD8T cells, we could not rule out the
possibility that IL-4Rα+ CD8+ T cells in CD4+ T cell specific IL-
4Rα− deficient mice could have contributed to infection control,
especially since CD8+ T cells have been implicated in protective
immunity to VL (15, 30). Thus, we sought to investigate this
further by using pan T cell specific IL-4Rα-deficient mice
(iLckcreIL-4Rα−/lox) which lack IL-4Rα signaling on CD4T cells
as well as CD8 and Foxp3 regulatory T cells (33). iLckcreIL-
4Rα−/lox, IL-4Rα−/lox littermate control and global IL-4Rα−/−
mice were infected with L. donovani and parasite burdens
analyzed at day 30 p.i. in the spleen, liver, and bone-marrow.
All groups of animals exhibited similar parasite numbers in the
spleen and bone-marrow at day 30 p.i. However, pan T cell IL-
4Rα−/lox exhibited disease-control in the liver compared with
WT littermate controls (p< 0.01) and global IL-4Rα−/− mice (p
< 0.01, Table 1), similar to but more pronounced than that seen
in CD4+ T cell-specific IL-4Rα-deficient mice (Figure 1A).
Frontiers in Immunology | www.frontiersin.org 7 August 2019 | Volume 10 | Article 1957
McFarlane et al. IL-4Rα+ T Cells in Visceral Leishmaniasis
FIGURE 5 | Serum IL-10 levels in wild-type control mice (IL-4Rα−/lox), CD4+ T cell specific IL-4Rα deficient mice (Lckcre IL-4Rα−/lox) and global IL-4Rα−/− over the
course of infection were determined by ELISA against Leishmania donovani soluble antigen. Representative data from one of two experiments performed (n =
5/group). **p < 0.01 compared to WT control (IL-4Rα−/lox), #p < 0.05 Lckcre IL-4Rα−/lox compared to IL-4Rα−/−.
Altogether, these data indicate that IL-4Rα signaling on T cells
transiently exacerbates infection in the liver after infection with
L. donovani. These results also reinforce the ability of IL-4/IL-
13 to exhibit temporal and spatial regulation depending on cell-
type and host tissue involved during infection. However, given
that IL-4/IL-13 signaling globally is protective in VL, our results
clearly demonstrate that the T cell is ultimately not the IL-4Rα
responsive target mediating this protection.
DISCUSSION
While it is well-established that protective immunity against
leishmaniasis, whether cutaneous or visceral, relies upon an
IL-12-driven type 1 response and IFN-γ production, the
contribution of IL-4, IL-13, and signaling via IL-4Rα to
the outcome of Leishmania infection is very much parasite-
species dependent [reviewed (21, 40)]. Numerous studies have
identified detrimental roles for IL-4, IL-13, and signaling via
IL-4Rα, as well as IL-10, during cutaneous infection with L.
major and Leishmania mexicana complex parasites. In contrast,
experimental studies using gene-deficient mice in L. donovani
infections have indicated that the control of not only primary
infection, but also successful chemotherapy and successful
vaccination is IL-4, IL-13, and IL-4Rα signaling-dependent (15–
17, 32). The absence of these cytokines, or the inability to signal
via the IL-4Rα in BALB/c mice, results in a reduced IFN-γ
response, severely limited granuloma development, enhanced IL-
10 production and disease exacerbation. However, the mode of
action of these cytokines continues to remain obscure as IL-4 and
IL-13 are pleiotropic cytokines and many cell types are not only
able to produce these cytokines but also are responsive to them
via IL-4Rα (21). Consequently, the generation of spatial (cell-
specific) IL-4Rα−/− mice has provided an invaluable resource
to identify the specific role of IL-4/IL-13-responding cells in
ongoing immune responses (15, 17, 19). A previous study by us
using macrophage/neutrophil specific IL-4Rα-deficient BALB/c
mice identified no role, whether protective or detrimental, for IL-
4 or IL-13 signaling via these cells on the outcome of primary
L. donovani infection (16). T cells are the primary source of
IFN-γ production in acquired immunity against VL (30), and
have been implicated as playing a major role in granuloma
formation and resolution of infection in the murine model
(39). Therefore, in the present study we utilized CD4+ T cell-
specific IL-4Rα-deficient (LckcreIL-4Rα−/lox) mice (23), and as
confirmation iLckcreIL-4Rα−/lox mice that lack IL-4Rα on both
CD4+and CD8+ T cells (33) to determine if IL-4Rα signaling
via T cells plays any important role in protection. The results
reveal that IL-4Rα signaling via the CD4+ T cell is not a
requirement for successful resolution of L. donovani infection,
but the inability to signal via IL-4Rα did have a transient
protective effect (day 30) on hepatic parasite burdens compared
with wild-type counterparts. This hepatic protective effect was
also observed in pan-T cell specific BALB/c mice i.e., iLckcreIL-
4Rα−/lox BALB/c mice, confirming that this early response is
mediated by IL-4Rα signaling on T cells. However, later post-
infection, CD4+ T cell specific IL-4Rα-deficient mice and wild-
type controls had equivalent parasite burdens in the spleen, liver
and bone marrow as well as a similar hepatic granulomatous
response. This is in contrast to global IL-4Rα−/− mice that
developed significantly higher parasite burdens and abrogated
hepatic granuloma maturation compared with CD4+ T cell
specific IL-4Rα-deficient and wild-type mice in all tissue sites.
Overall these data suggest that host-protection mediated by IL-
4/IL-13 globally during L. donovani infection is not due to IL-4
acting on CD4+ T cell populations.
Earlier studies on L. donovani, not only in mice (9), but
also humans (10–12), suggested that control of infection was
independent of the differential production of type 1 and type 2
cytokines and murine studies indicate that protection is related
to increasing the frequency of cytokine-producing cells rather
than altering the IFN-γ/IL-4 balance (13). The results presented
here confirm that resistance to L. donovani and induction
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FIGURE 6 | The effect of L. donovani infection on the antibody response of L. donovani infected CD4+ T cell specific IL-4Rα deficient (Lckcre IL-4Rα−/lox ), wild-type
control (IL-4Rα−/lox), and global IL-4Rα−/− mice. Antigen-specific IgG1 (A), IgG2a (B), the ratio of antigen-specific IgG2a/IgG1 (C) and total IgE serum levels are
shown (D). Specific antibody titers were determined using an antigen-specific ELISA and total IgE levels were also determined using a direct ELISA assay. *p < 0.05,
**p < 0.01, ***p < 0.001 compared to WT control (IL-4Rα−/lox), #p < 0.01, ##p < 0.01, ###p < 0.001 Lckcre IL-4Rα−/lox compared to IL-4Rα−/−. Representative
data from one of two experiments performed (n = 5/group).
of effective granuloma production is dependent on successful
generation of an IFN-γ response on both CD4+ and CD8+
T cells and while this is positively regulated by IL-4/IL-13
signaling on a global scale, it is not strictly dependent on
CD4+ and CD8+ T cells signaling these cytokines. CD4+
T cells (26, 39) and CD8+ T cells (41) produce IFN-γ,
which activates macrophages to produce antimicrobial reactive
nitrogen and oxygen intermediates (7), and these are also
important in driving granuloma maturation. The observations
on comparative T cell IFN-γ expressing cell numbers from
this study complement and reinforce our previous observation
that global IL-4Rα−/− mice produce significantly lower levels
of serum IFN-γ compared with wild-type mice following L.
donovani infection, and contribute to their abrogated granuloma
development (15).
In parallel, although IL-4 is important in proliferation and
maintenance of CD4+ Th2 cells, it is not required for early
production of Th2 cells (42, 43), and therefore the inability to
signal via the IL-4Rα did not prevent the induction of antigen-
specific Th2 cell response, shown by the similar antigen-specific
IgG1 titers in L. donovani infected WT and CD4+ T cell-
specific IL-4Rα-deficient (LckcreIL-4Rα−/lox) mice. This may not
be unexpected as it has been suggested that antigen-specific Th2
cells is the default position for Th cells (41). The ability to produce
antigen-specific IgG1 in the absence of IL-4Rα signaling has been
reported in other studies (39, 40).
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TABLE 1 | Parasite burdens of WT (IL-4Rα−/lox), pan T cell IL-4Rα-deficient
(iLckcre IL-4Rα−/lox), and IL-4Rα−/− deficient BALB/c mice in the spleen, liver
and bone marrow.
Strain Mean parasite burden (+ SD)
Spleen Liver Bone marrow
IL-4Rα−/lox 329 ± 87 2554 ± 334 645 ± 94
iLckcre IL-4Rα−/lox 285 ± 47 1040 ± 376** 494 ± 77
IL-4Rα−/− 509 ± 87 2279 ± 376# 875 ± 145
Mice (n = 5/treatment) were infected with L. donovani LV82 and parasite burdens
were determined on day 30 post-infection. **p < 0.001 compared to WT control,
**p < 0.01 compared to WT control, #p < 0.01 iLckcre IL-4Rα−/lox compared
to IL-4Rα−/−.
Recently, a pivotal role for IL-4 and IL-4Rα-responsive B
cells in the non-healing response of BALB/c mice infected with
L. major has been demonstrated (25). Abrogation of IL-4Rα
signaling on B cells in BALB/c mice (mb1creIL-4Rα−/lox) turned
non-healer BALB/c mice into a healer phenotype concomitant
with a switch from a predominately Th2 to a Th1 response.
Regulatory B cells producing IL-10 have also been associated
with non-healing L. major infection (44) although apparently not
associated with IL-4 responsiveness. However, the role of B cells
(as APCs or regulatory cells) and/or antibody in contributing to
susceptibility to Leishmania infection appears to depend in large
part upon the parasite species examined but also probably to a
significant extent upon the host. B cells have been shown to play
a role in VL, thus B cell-deficient C57BL/6 mice infected with
L. donovani (45) and BALB/c mice infected with L. infantum
(46) are relatively resistant to infection. Susceptibility to infection
in B cell deficient C57BL/6 mice, unlike BALB/c mice is not
dependent on antibody production, although antibodies are
associated with protection in infected C57BL/6 mice as they
prevent excessive pathology. Marginal zone B cells regulate
antigen-specific CD8+ T cells responses (47), indicating that
B cells may be protective via their ability to present antigen.
In L. infantum-infected BALB/c mice, neither IL-10 production
by B cells nor antigen presentation by B cells is involved in
disease exacerbation. However, passive transfer experiments have
shown that IgM and IgG, induced by polyclonal B cell activation
during infection, promote parasite growth. It is possible that the
role of B cells differs in the two mouse strains and is related
to their inherent “cure” phenotype (C57BL/6) and “non-cure”
phenotype in L. donovani (48). B cells have been observed to
have cognate interactions with T cells in hepatic granulomas in
BALB/c mice (28) and problems with antigen presentation to
CD8+ T cells have been reported in L. donovani (30). There
were clear differences in antibody responses between global IL-
4Rα−/− mice and the other two strains, with differences in
total IgE and antigen-specific IgG1 being the most marked.
Production of these antibody classes by B cells is known to be
controlled by IL-4/IL-13 and requires IL-4Rα signaling (49). The
fact that CD4+ T cell specific IL-4Rα−/− mice can still produce
IgE indicates that a comparative examination of L. donovani
disease phenotypes in B cell specific IL-4Rα−/lox BALB/ c mice
would be worthwhile.
Both human (12) and murine studies (14, 50) indicate that
IL-10, rather than IL-4/IL-13 is the major immunosuppressive
cytokine in VL. The source of this IL-10 is not traditional Th2
cells (13) but perhaps a regulatory T cell population (51), and
different types of regulatory T cells have been identified in L.
donovani, including CD4+CD25−FoxP3− T cells in humans
(52), and CD4+CD25−FoxP3+ in mice (53) and humans (54).
In addition, numerous non-T cell populations, including DCs
(55) and NK cells (56) have been implicated as playing regulatory
roles during VL. Thus, L. donovani infected IL-10 gene deficient
mice demonstrated increased control over visceral infection
and enhanced granuloma formation, whilst IL-10 transgenic
mice developed a severe progressive disease (50, 57) clearly
demonstrating that the presence of IL-10 can prevent efficient
granuloma development (50). Indeed, in the present study, global
IL-4Rα−/− mice had impaired hepatic granuloma development
alongside elevated serum IL-10 levels compared with wild-
type control mice and CD4+ T cell specific IL-4Rα−/− mice.
Interestingly it has previously been shown that IL-4 inhibits
IL-10 to promote IL-12 production in DCs in the presence of
CpG or LPS (58), or Cryptococcus neoformans (59), while IL-13
can induce DC IL-12 production in vitro when used to prime
DC prior to LPS stimulation (16). IL-4 treatment of BALB/c
mice pre-T cell priming has previously been demonstrated to
instruct DC to produce IL-12 and facilitate a protective Th1
response against L. major (60). In addition, deletion of IL-
4Rα on DCs renders BALB/c mice hypersusceptible to L. major
(22). DC IL-12 production in the early phase of L. donovani
infection (61–64), in particular, has been identified as directing
immune responses influencing granuloma formation during
infection. Consequently, these observations, collectively, would
clearly point to DCs as very probable targets of the IL-4/IL-
13 induced protective response identified from our studies on
IL-4−/−, IL-13−/−, and IL-4Rα−/− mice.
CONCLUSION
A significant number of studies from our laboratories
have identified protective roles for IL-4, IL-13 and IL-4Rα
signaling, not merely during primary infection with L. donovani
infection (15–17), but also for effective sodium stibogluconate
chemotherapy (16, 19). In addition, there is a requirement on
IL-4/IL-13 to instruct a protective type 1 response mediated
by CD8+ T cells in HASPB-1 vaccination against L. donovani
(65). Given the pleiotropic nature of the IL-4Rα, these IL-4Rα-
responsive cells could of course be different populations in
different tissue sites and could vary for different type of immune
responses e.g., primary infection, response to chemotherapy or
successful vaccination. In lieu of this dynamic regulation, as yet
our studies have failed to identify the IL-4Rα-expressing cells
mediating protection during VL. So far we have ruled out a
protective role in VL for IL-4Rα responsiveness on neutrophils
and macrophages in primary infection and chemotherapy,
and herein T cells during primary infection. Interestingly,
the primary source of IL-4 in HASPB-1 vaccination studies
was defined as a CD11b+CD11clo phagocyte (65) and as this
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source is clearly not macrophages/neutrophils (16), alternate
phagocytes expressing CD11b may regulate host immunity to
VL. A candidate phagocyte for this role could be DCs given
the “IL-4 instruction theory,” defined as the ability of early
IL-4, signaling via the IL-4Rα on DCs, to instruct early IL-12
production to promote Th1-responses (22, 60). We are currently
investigating the exact mechanism to explain how this works
as well as generating a variety of additional IL-4Rα cell specific
knockouts to allow further dissection of the immunological
mechanisms responsible for IL-4Rα mediated protection against
VL. Ultimately identifying the IL-4Rα responsive host cells
mediating protection will have significant implications in the
rational design of new host-directed therapeutic strategies.
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